Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications

References

• Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• World Health Organization Fact Sheet. WHO Health Emergency Dashboard. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed April 8, 2021.
   Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: pathogenesis, cytokine storm, and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66–70. doi:10.1016/j.cytogfr.2020.05.002
   PubMed Web of Science ®Google Scholar
• Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020;6:11. doi:10.1038/s41421-020-0147-1
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi:10.1016/S0140-6736(20)30251-8
   PubMed Web of Science ®Google Scholar
• Rowaiye AB, Onuh OA, Oli AN, Okpalefe OA, Oni S, Nwankwo EJ. The pandemic COVID-19: a tale of viremia, cellular oxidation, and immune dysfunction. Pan Afr Med J. 2020;36:188. doi:10.11604/pamj.2020.36.188.23476
   PubMed Web of Science ®Google Scholar
• Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42. doi:10.1016/j.cytogfr.2020.04.002
   PubMed Web of Science ®Google Scholar
• Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446. doi:10.3389/fimmu.2020.01446
   PubMed Web of Science ®Google Scholar
• Bhaskar S, Sinha A, Banach M, et al. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: the REPROGRAM Consortium Position Paper. Front Immunol. 2020;11:1648. doi:10.3389/fimmu.2020.01648
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–329. doi:10.7150/thno.49713
   PubMed Web of Science ®Google Scholar
• Eccleston-Turner M, Phelan A, Katz R. Preparing for the Next Pandemic - The WHO’s Global Influenza Strategy. N Engl J Med. 2019;381(23):2192–2194. doi:10.1056/NEJMp1905224
   PubMed Web of Science ®Google Scholar
• Teijaro JR, Walsh KB, Rice S, Rosen H, Oldstone MB. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci USA. 2014;111(10):3799–3804. doi:10.1073/pnas.1400593111
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. doi:10.1186/s40779-020-0233-6
   PubMed Web of Science ®Google Scholar
• Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32. doi:10.1128/MMBR.05015-11
   PubMed Web of Science ®Google Scholar
• Ciavarella C, Motta I, Valente S, Pasquinelli G. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease. Molecules. 2020;25(9):2076. doi:10.3390/molecules25092076
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613. doi:10.1016/j.jinf.2020.03.037
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19(2):181–193. doi:10.1016/j.chom.2016.01.007
   PubMed Web of Science ®Google Scholar
• Davidson S, Maini MK, Wack A. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interferon Cytokine Res. 2015;35(4):252–264. doi:10.1089/jir.2014.0227
   PubMed Web of Science ®Google Scholar
• Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol. 2013;13(12):875–887. doi:10.1038/nri3547
   PubMed Web of Science ®Google Scholar
• Li S, Zhang Y, Guan Z, et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther. 2020;5(1):235. doi:10.1038/s41392-020-00334-0
   PubMed Web of Science ®Google Scholar
• Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17–41. doi:10.1002/JLB.3COVR0520-272R
   PubMed Web of Science ®Google Scholar
• Yang D, Chu H, Hou Y, et al. Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells Is Associated with Viral Antagonism of STAT1 Phosphorylation. J Infect Dis. 2020;222(5):734–745. doi:10.1093/infdis/jiaa356
   PubMed Web of Science ®Google Scholar
• Kim ES, Choe PG, Park WB, et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. J Korean Med Sci. 2016;31(11):1717–1725. doi:10.3346/jkms.2016.31.11.1717
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homolog of angiotensin-converting enzyme. FEBS Lett. 2002;532(1–2):107–110. doi:10.1016/s0014-5793(02)03640-2
   PubMed Web of Science ®Google Scholar
• Niu W, Qi Y, Hou S, Zhou W, Qiu C. Correlation of angiotensin-converting enzyme two gene polymorphisms with stage 2 hypertension in Han Chinese. Transl Res. 2007;150(6):374–380. doi:10.1016/j.trsl.2007.06.002
   PubMed Web of Science ®Google Scholar
• Chen YY, Liu D, Zhang P, et al. Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors. J Hum Hypertens. 2016;30(12):766–771. doi:10.1038/jhh.2016.24
   PubMed Web of Science ®Google Scholar
• Wysocki J, Ye M, Soler MJ, et al. ACE and ACE2 activity in diabetic mice. Diabetes. 2006;55(7):2132–2139. doi:10.2337/db06-0033
   PubMed Web of Science ®Google Scholar
• IIwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14(5):315–328. doi:10.1038/nri3665
   PubMed Web of Science ®Google Scholar
• Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128. doi:10.1038/s41392-020-00243-2
   PubMed Web of Science ®Google Scholar
• Xagorari A, Chlichlia K. Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J. 2008;2(1):49–59. doi:10.2174/1874285800802010049
   PubMedGoogle Scholar
• Wurfel MM, Gordon AC, Holden TD, et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med. 2008;178(7):710–720. doi:10.1164/rccm.200803-462OC
   PubMed Web of Science ®Google Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi:10.1126/science
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. doi:10.1126/science
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32(1):513–545. doi:10.1146/annurev-immunol-032713-120231
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem. 2007;141(2):137–145. doi:10.1093/jb/mvm032
   PubMed Web of Science ®Google Scholar
• Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. doi:10.1016/j.antiviral.2020.104791
   PubMed Web of Science ®Google Scholar
• Reiter Z. Interferon–a major regulator of natural killer cell-mediated cytotoxicity. J Interferon Res. 1993;13(4):247–257. doi:10.1089/jir.1993.13.247
   PubMedGoogle Scholar
• Shibabaw T, Molla MD, Teferi B, Ayelign B. Role of IFN and Complements System: innate Immunity in SARS-CoV-2. J Inflamm Res. 2020;13:507–518. doi:10.2147/JIR.S267280
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718–724. doi:10.1126/science.abc6027
   PubMed Web of Science ®Google Scholar
• Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 2005;86:209–239. doi:10.1016/S0065-2776(04)86006-1
   PubMed Web of Science ®Google Scholar
• Rowaiye AB, Asala T, Oli AN, Uzochukwu IC, Akpa A, Esimone CO. The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials. Curr Drug Targets. 2020;21(16):1733–1751. doi:10.2174/1389450121666200910160929
   PubMed Web of Science ®Google Scholar
• Soe WM, Lim JHJ, Williams DL, et al. Using Expanded Natural Killer Cells as Therapy for Invasive Aspergillosis. J Fungi. 2020;6(4):231. doi:10.3390/jof6040231
   Web of Science ®Google Scholar
• Vandenhaute J, Wouters CH, Matthys P. Natural Killer Cells in Systemic Autoinflammatory Diseases: a Focus on Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome. Front Immunol. 2020;10:3089. doi:10.3389/fimmu.2019.03089
   PubMed Web of Science ®Google Scholar
• Jenkins MR, Rudd-Schmidt JA, Lopez JA, et al. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015;212(3):307–317. doi:10.1084/jem.20140964
   PubMed Web of Science ®Google Scholar
• Brisse E, Wouters CH, Matthys P. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. Br J Haematol. 2016;174(2):203–217. doi:10.1111/bjh.14147
   PubMed Web of Science ®Google Scholar
• Sepulveda FE, Debeurme F, Ménasché G, et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood. 2013;121(4):595–603. doi:10.1182/blood-2012-07-440339
   PubMed Web of Science ®Google Scholar
• Trapani JA, Voskoboinik I, Jenkins MR. Perforin-dependent cytotoxicity: ‘Kiss of death’ or prolonged embrace with darker elocation-idnseque11es? Oncoimmunology. 2015;4(9):e1036215. doi:10.1080/2162402X.2015.1036215
   PubMed Web of Science ®Google Scholar
• Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am. 2012;59(2):329–344. doi:10.1016/j.pcl.2012.03.002
   PubMed Web of Science ®Google Scholar
• Voskoboinik I, Trapani JA. Perforinopathy: a spectrum of human immune disease caused by defective perforin delivery or function. Front Immunol. 2013;4:441. doi:10.3389/fimmu.2013.00441
   PubMed Web of Science ®Google Scholar
• Rex J, Lutz A, Faletti LE, et al. IL-1β and TNFα Differentially Influence NF-κB Activity and FasL-Induced Apoptosis in Primary Murine Hepatocytes During LPS-Induced Inflammation. Front Physiol. 2019;10:117. doi:10.3389/fphys.2019.00117
   PubMed Web of Science ®Google Scholar
• Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013;12(1):86. doi:10.1186/1476-4598-12-86
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Sig Transduct Target Ther. 2017;2:17023. doi:10.1038/sigtrans.2017.23
   PubMed Web of Science ®Google Scholar
• Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The Role of Interleukin 6 During Viral Infections. Front Microbiol. 2019;10:1057. doi:10.3389/fmicb.2019.01057
   PubMed Web of Science ®Google Scholar
• Lacroix M, Rousseau F, Guilhot F, et al. Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex. J Biol Chem. 2015;290(45):26943–26953. doi:10.1074/jbc.M115.682138
   PubMed Web of Science ®Google Scholar
• Tamura K, Kanazawa T, Tsukada S, Kobayashi T, Kawamura M, Morikawa A. Increased serum monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, and interleukin-8 concentrations in hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;51(5):662–668. doi:10.1002/pbc.21660
   PubMed Web of Science ®Google Scholar
• Takada H, Takahata Y, Nomura A, Ohga S, Mizuno Y, Hara T. Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin Exp Immunol. 2003;133(3):448–453. doi:10.1046/j.1365-2249.2003.02237
   PubMed Web of Science ®Google Scholar
• Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89(11):4100–4103. doi:10.1182/blood.V89.11.4100
   PubMed Web of Science ®Google Scholar
• Briso EM, Dienz O, Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol. 2008;180(11):7102–7106. doi:10.4049/jimmunol.180.11.7102
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014;10(12):720–727. doi:10.1038/nrrheum.2014.127
   PubMed Web of Science ®Google Scholar
• Ott LW, Resing KA, Sizemore AW, et al. Tumor Necrosis Factor-alpha- and interleukin-1-induced cellular responses: coupling proteomic and genomic information. J Proteome Res. 2007;6(6):2176–2185. doi:10.1021/pr060665l
   PubMed Web of Science ®Google Scholar
• Tsang K, Zhong NS. SARS: pharmacotherapy. Respirology. 2003;8(Suppl):S25–S30. doi:10.1046/j.1440-1843.2003.00525
   PubMedGoogle Scholar
• Chien JY, Hsueh PR, Cheng WC, Yu CJ, Yang PC. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology. 2006;11(6):715–722. doi:10.1111/j.1440-1843.2006.00942
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19 cytokine storm: the anger of inflammation. Cytokine. 2020;133:155151. doi:10.1016/j.cyto.2020.155151
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. National Sci Rev. 2020;7(6):998–1002. doi:10.1093/nsr/nwaa041
   PubMed Web of Science ®Google Scholar
• Yang Y, Shen C, Li J, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020;146(1):119–127.e4. doi:10.1016/j.jaci.2020.04.027
   PubMed Web of Science ®Google Scholar
• Herrero R, Sanchez G, Lorente JA. New insights into the mechanisms of pulmonary edema in acute lung injury. Ann Transl Med. 2018;6(2):32. doi:10.21037/atm.2017.12.18
   PubMed Web of Science ®Google Scholar
• Wee JL, Greenwood DL, Han X, Scheerlinck JP. Inflammatory cytokines IL-6 and TNF-α regulate lymphocyte trafficking through the local lymph node. Vet Immunol Immunopathol. 2011;144(1–2):95–103. doi:10.1016/j.vetimm.2011.07.007
   PubMed Web of Science ®Google Scholar
• Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517–1520. doi:10.1016/S0140-6736(20)30920-X
   PubMed Web of Science ®Google Scholar
• Maeda K, Baba Y, Nagai Y, et al. IL-6 blocks a discrete early step in lymphopoiesis. Blood. 2005;106(3):879–885. doi:10.1182/blood-2005-02-0456
   PubMed Web of Science ®Google Scholar
• Maeda K, Malykhin A, Teague-Weber BN, Sun XH, Farris AD, Coggeshall KM. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6. Sle1.Yaa animals. Blood. 2009;113(19):4534–4540. doi:10.1182/blood-2008-12-192559
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi:10.1186/s40425-018-0343-9
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959–970. doi:10.2217/imt-2016-0020
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457. doi:10.1038/ni.3153
   PubMed Web of Science ®Google Scholar
• Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004;363(9404):203–209. doi:10.1016/S0140-6736(03)15326-3
   PubMed Web of Science ®Google Scholar
• Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med. 2015;66:145–159. doi:10.1146/annurev-med-061813-012806
   PubMed Web of Science ®Google Scholar
• Sieni E, Cetica V, Hackmann Y, et al. Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on immune system functioning. Front Immunol. 2014;5:167. doi:10.3389/fimmu.2014.00167
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi:10.1182/blood-2014-05-552729
   PubMed Web of Science ®Google Scholar
• Khadka RH, Sakemura R, Kenderian SS, Johnson AJ. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 2019;11(10):851–857. doi:10.2217/imt-2019-0074
   PubMed Web of Science ®Google Scholar
• Poggiali E, Zaino D, Immovilli P, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta. 2020;509:135–138. doi:10.1016/j.cca.2020.06.012
   PubMed Web of Science ®Google Scholar
• Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. Insights into the Use of C-Reactive Protein as a Diagnostic Index of Disease Severity in COVID-19 Infections. Am J Trop Med Hyg. 2020;103(2):561–563. doi:10.4269/ajtmh.20-0473
   PubMed Web of Science ®Google Scholar
• Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014;6(4):748–773. doi:10.1039/c3mt00347g
   PubMed Web of Science ®Google Scholar
• Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest. 2002;121(4):1262–1268. doi:10.1378/chest.121.4.1262
   PubMed Web of Science ®Google Scholar
• Nehring SM, Goyal A, Bansal P, et al. C Reactive Protein. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Available from https://www.ncbi.nlm.nih.gov/books/NBK441843/. Accessed November 4th, 2020.
   Google Scholar
• Bertolini A, van de Peppel IP, Bodewes FAJA, et al. Abnormal Liver Function Tests in Patients with COVID-19: relevance and Potential Pathogenesis. Hepatology. 2020. doi:10.1002/hep.31480
   PubMed Web of Science ®Google Scholar
• Mandel M, Harari G, Gurevich M, Achiron A. Cytokine prediction of mortality in COVID19 patients. Cytokine. 2020;134:155190. doi:10.1016/j.cyto.2020.155190
   PubMed Web of Science ®Google Scholar
• O’Neill CM, Lu C, Corbin KL, et al. Nunemaker CS. Circulating levels of IL-1B+IL-6 cause ER stress and dysfunction in islets from prediabetic male mice. Endocrinology. 2013;154(9):3077–3088. doi:10.1210/en.2012-2138
   PubMed Web of Science ®Google Scholar
• Grifoni E, Valoriani A, Cei F, et al. Interleukin-6 as prognosticator in patients with COVID-19. J Infect. 2020;81(3):452–482. doi:10.1016/j.jinf.2020.06.008
   PubMed Web of Science ®Google Scholar
• Li G, Wu W, Zhang X, et al. Serum levels of tumor necrosis factor-alpha in patients with IgA nephropathy are closely associated with disease severity. BMC Nephrol. 2018;19(1):326. doi:10.1186/s12882-018-1069-0
   PubMedGoogle Scholar
• Kong M, Zhang H, Cao X, Mao X, Lu Z. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol Infect. 2020;148:e139. doi:10.1017/S0950268820001557
   PubMed Web of Science ®Google Scholar
• Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205–1208. doi:10.1007/s00277-020-04019-0
   PubMed Web of Science ®Google Scholar
• Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401–409. doi:10.1093/intimm/dxx031
   PubMed Web of Science ®Google Scholar
• Vargas-Vargas M, Cortés-Rojo C. Ferritin levels and COVID-19. Rev Panam Salud Publica. 2020;44:e72. doi:10.26633/RPSP.2020.72
   PubMed Web of Science ®Google Scholar
• Gómez-Pastora J, Weigand M, Kim J, et al. Hyperferritinemia in critically ill COVID-19 patients - Is ferritin the product of inflammation or a pathogenic mediator? Clin Chim Acta. 2020;509:249–251. doi:10.1016/j.cca.2020.06.033
   PubMed Web of Science ®Google Scholar
• Shaw TY, Schivo M. Weathering a Cytokine Storm: a Case of EBV-Induced Hemophagocytic Lymphohistiocytosis. J Investig Med High Impact Case Rep. 2016;4(2):2324709616647409. doi:10.1177/2324709616647409
   Google Scholar
• Magro G. Cytokine Storm: is it the only major death factor in COVID-19 patients? Coagulation role. Med Hypotheses. 2020;142:109829. doi:10.1016/j.mehy.2020.109829
   PubMed Web of Science ®Google Scholar
• Pagana KD, Pagana TJ, Pagana TN. Mosby’s Diagnostic and Laboratory Test Reference. 14th ed. St Louis, MO: Elsevier; 2019.
   Google Scholar
• Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–1329. doi:10.1111/jth.14859
   PubMed Web of Science ®Google Scholar
• Yu B, Li X, Chen J, et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis. 2020;50(3):548–557. doi:10.1007/s11239-020-02171-y
   PubMed Web of Science ®Google Scholar
• Chhetri S, Khamis F, Pandak N, Al Khalili H, Said E, Petersen E. A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm). IDCases. 2020;21:e00829. doi:10.1016/j.idcr
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: an Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20(13):3328. doi:10.3390/ijms20133328
   PubMed Web of Science ®Google Scholar
• Erra Díaz F, Dantas E, Geffner J. Unravelling the Interplay between Extracellular Acidosis and Immune Cells. Mediators Inflamm. 2018;2018:1218297. doi:10.1155/2018/1218297
   PubMed Web of Science ®Google Scholar
• Wu MY, Yao L, Wang Y, et al. Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Respir Res. 2020;21(1):171. doi:10.1186/s12931-020-01427-8
   PubMed Web of Science ®Google Scholar
• Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6(1):4. doi:10.1186/s40364-018-0116-0
   PubMedGoogle Scholar
• Fan Z, Chen L, Li J, et al. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561–1566. doi:10.1016/j.cgh.2020.04.002
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020;8(5):509–519. doi:10.1177/2050640620924157
   PubMed Web of Science ®Google Scholar
• Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998–1004. doi:10.1111/liv.14435
   PubMed Web of Science ®Google Scholar
• Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;73(3):566–574. doi:10.1016/j.jhep.2020.04.006
   PubMed Web of Science ®Google Scholar
• Morgan DB, Carver ME, Payne RB. Plasma creatinine and urea: creatinine ratio in patients with raised plasma urea. Br Med J. 1977;2(6092):929–932. doi:10.1136/bmj.2.6092.929
   PubMed Web of Science ®Google Scholar
• Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–430. doi:10.1016/S2468-1253(20)30057-1
   PubMed Web of Science ®Google Scholar
• Gulen M, Satar S. Uncommon presentation of COVID-19: gastrointestinal bleeding. Clin Res Hepatol Gastroenterol. 2020;44(4):e72–e76. doi:10.1016/j.clinre.2020.05.001
   PubMed Web of Science ®Google Scholar
• Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of fecal transmission. Aliment Pharmacol Ther. 2020;51(9):843–851. doi:10.1111/apt.15731
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5
   PubMed Web of Science ®Google Scholar
• Cheng A, Hu L, Wang Y, et al. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. Int J Antimicrob Agents. 2020;56(3):106110. doi:10.1016/j.ijantimicag.2020.106110
   PubMed Web of Science ®Google Scholar
• Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail. 2011;13(11):1161–1171. doi:10.1093/eurjhf/hfr122
   PubMed Web of Science ®Google Scholar
• Yang J, Liao X, Yin W, et al. Elevated cardiac biomarkers may be effective prognostic predictors for patients with COVID-19: a multicenter, observational study. Am J Emerg Med. 2021;39:34–41. doi:10.1016/j.ajem.2020.10.013
   Web of Science ®Google Scholar
• Shi L, Wang Y, Wang Y, Duan G, Yang H. Meta-Analysis of Relation of Creatine kinase-MB to Risk of Mortality in Coronavirus Disease 2019 Patients. Am J Cardiol. 2020;130:163–165. doi:10.1016/j.amjcard.2020.06.004
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–1643. doi:10.1038/s41591-020-1051-9
   PubMed Web of Science ®Google Scholar
• Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123–1130. doi:10.1080/22221751.2020.1770129
   PubMed Web of Science ®Google Scholar
• Wu D, Dinh TL, Bausk BP, Walt DR. Long-Term Measurements of Human Inflammatory Cytokines Reveal Complex Baseline Variations between Individuals. Am J Pathol. 2017;187(12):2620–2626. doi:10.1016/j.ajpath.2017.08.007
   PubMed Web of Science ®Google Scholar
• Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133(9):1032–1038. doi:10.1097/CM9.0000000000000775
   PubMed Web of Science ®Google Scholar
• Tan A, Sullenbarger B, Prakash R, McDaniel JC. Supplementation with eicosapentaenoic acid and docosahexaenoic acid reduces high levels of circulating proinflammatory cytokines in aging adults: a randomized, controlled study. Prostaglandins Leukot Essent Fatty Acids. 2018;132:23–29. doi:10.1016/j.plefa.2018.03.010
   PubMed Web of Science ®Google Scholar
• He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005;9(6):323–330. doi:10.1016/j.ijid.2004.07.014
   PubMed Web of Science ®Google Scholar
• Hottz ED, Bozza FA, Bozza PT. Platelets in Immune Response to Virus and Immunopathology of Viral Infections. Front Med. 2018;5:121. doi:10.3389/fmed.2018.00121
   Web of Science ®Google Scholar
• Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology. 2021;88(1):15–27. doi:10.1159/000512007
   PubMed Web of Science ®Google Scholar
• Rayes J, Bourne JH, Brill A, Watson SP. The dual role of platelet-innate immune cell interactions in thrombo-inflammation. Res Pract Thromb Haemost. 2019;4(1):23–35. doi:10.1002/rth2.12266
   PubMed Web of Science ®Google Scholar
• Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of hematopoietic stem cells. Nature. 2004;431(7011):997–1002. doi:10.1038/nature02989
   PubMed Web of Science ®Google Scholar
• Tishkowski K, Gupta V. Erythrocyte Sedimentation Rate. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available from https://www.ncbi.nlm.nih.gov/books/NBK557485/. Accessed February 27, 2021.
   Google Scholar
• Al Musawi MS, Jaafar MS, Al-Gailani B, Ahmed NM, Suhaimi FM, Bakhsh M. Erythrocyte sedimentation rate of human blood exposed to low-level laser. Lasers Med Sci. 2016;31(6):1195–1201. doi:10.1007/s10103-016-1972-1
   PubMed Web of Science ®Google Scholar
• Kim PS, Read SW, Fauci AS. Therapy for Early COVID-19: a Critical Need. JAMA. 2020;324(21):2149–2150. doi:10.1001/jama.2020.22813
   PubMed Web of Science ®Google Scholar
• Sahu KK, Kumar R. Preventive and treatment strategies of COVID-19: from community to clinical trials. J Family Med Prim Care. 2020;9(5):2149–2157. doi:10.4103/jfmpc.jfmpc_728_20
   PubMedGoogle Scholar
• Stahl EC, Brown BN. Cell Therapy Strategies to Combat Immunosenescence. Organogenesis. 2015;11(4):159–172. doi:10.1080/15476278.2015.1120046
   PubMed Web of Science ®Google Scholar
• Das S, Anu KR, Birangal SR, et al. Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: a review. Life Sci. 2020;258:118202. doi:10.1016/j.lfs.2020.118202
   PubMed Web of Science ®Google Scholar
• Burrage DR, Koushesh S, Sofat N. Immunomodulatory Drugs in the Management of SARS-CoV-2. Front Immunol. 2020;11:1844. doi:10.3389/fimmu.2020.01844
   PubMed Web of Science ®Google Scholar
• Hojyo S, Fukada T. Roles of Zinc Signaling in the Immune System. J Immunol Res. 2016;2016:6762343. doi:10.1155/2016/6762343
   PubMed Web of Science ®Google Scholar
• Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol Med. 2008;14(5–6):353–357. doi:10.2119/2008-00033
   PubMed Web of Science ®Google Scholar
• Szabó Z, Marosvölgyi T, Szabó É, Bai P, Figler M, Verzár Z. The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease. Front Physiol. 2020;11:752. doi:10.3389/fphys.2020.00752
   PubMed Web of Science ®Google Scholar
• Baud D, Dimopoulou Agri V, Gibson GR, Reid G, Giannoni E. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic. Front Public Health. 2020;8:186. doi:10.3389/fpubh.2020.00186
   PubMed Web of Science ®Google Scholar
• Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. Pharma Nutrition. 2020;12:100190. doi:10.1016/j.phanu.2020.100190
   PubMed Web of Science ®Google Scholar
• Grant WB, Lahore H, McDonnell SL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020;12(4):988. doi:10.3390/nu12040988
   PubMed Web of Science ®Google Scholar
• Sheeja K, Kuttan G. Modulation of natural killer cell activity, antibody-dependent cellular cytotoxicity, and antibody-dependent complement-mediated cytotoxicity by andrographolide in normal and Ehrlich ascites carcinoma-bearing mice. Integr Cancer Ther. 2007;6(1):66–73. doi:10.1177/1534735406298975
   PubMed Web of Science ®Google Scholar
• Chicca A, Raduner S, Pellati F, et al. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol. 2009;9(7–8):850–858. doi:10.1016/j.intimp.2009.03.006
   PubMed Web of Science ®Google Scholar
• Rowe CA, Nantz MP, Bukowski JF, Percival SS. Specific formulation of Camellia sinensis prevents cold and flu symptoms and enhances gamma, delta T cell function: a randomized, double-blind, placebo-controlled study. J Am Coll Nutr. 2007;26(5):445–452. doi:10.1080/07315724.2007.10719634
   PubMed Web of Science ®Google Scholar
• Naseri N, Kalantar K, Amirghofran Z. Anti-inflammatory activity of Echium amoenum extract on macrophages mediated by inhibition of inflammatory mediators and cytokines expression. Res Pharm Sci. 2018;13(1):73–81. doi:10.4103/1735-5362.220970
   PubMed Web of Science ®Google Scholar
• Rowaiye AB, Oni SO, Uzochukwu IC, Akpa A, Esimone CO. The Structure-Based Virtual Screening for Natural Compounds that Bind with the Activating Receptors of Natural Killer Cells. Trop J Nat Prod Res. 2021;5(1):145–164. doi:10.26538/tjnpr/v5i1.21
   Google Scholar
• Broggi A, Ghosh S, Sposito B, et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020;369(6504):706–712. doi:10.1126/science.abc3545
   PubMed Web of Science ®Google Scholar
• Syedbasha M, Egli A. Interferon Lambda: modulating Immunity in Infectious Diseases. Front Immunol. 2017;8:119. doi:10.3389/fimmu.2017.00119
   PubMed Web of Science ®Google Scholar
• Alattar R, Ibrahim TBH, Shaar SH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020;92(10):2042–2049. doi:10.1002/jmv.25964
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–10975. doi:10.1073/pnas.2005615117
   PubMed Web of Science ®Google Scholar
• Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77(6):905–910. doi:10.1136/annrheumdis-2017-2128
   PubMed Web of Science ®Google Scholar
• Aouba A, Baldolli A, Geffray L, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. 2020;79(10):1381–1382. doi:10.1136/annrheumdis-2020-217706
   PubMed Web of Science ®Google Scholar
• Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013;12(9):688–702. doi:10.1038/nrd4099
   PubMed Web of Science ®Google Scholar
• Naz F, Arish M. Battling COVID-19 Pandemic: sphingosine-1-Phosphate Analogs as an Adjunctive Therapy? Front Immunol. 2020;11:1102. doi:10.3389/fimmu.2020.01102
   PubMed Web of Science ®Google Scholar
• Mehta P, Ciurtin C, Scully M, Levi M, Chambers RC. JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. Eur Respir J. 2020;56(3):2001919. doi:10.1183/13993003.01919-2020
   PubMed Web of Science ®Google Scholar
• La Rosée F, Bremer HC, Gehrke I, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34(7):1805–1815. doi:10.1038/s41375-020-0891-0
   PubMed Web of Science ®Google Scholar
• CTI Biopharma. CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19; 2020 Available from:https://cbc.gcs-web.com/news-releases/news-release-details/cti-biopharma-announces-initiation-phase-3-pre-vent-study. Accessed November 4th, 2020.
   Google Scholar
• Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–166. doi:10.1038/s41584-020-0372-x
   PubMed Web of Science ®Google Scholar
• Li X, Wang Y, Agostinis P, et al. Is hydroxychloroquine beneficial for COVID-19 patients? Cell Death Dis. 2020;11(7):512. doi:10.1038/s41419-020-2721-8
   PubMed Web of Science ®Google Scholar
• Parnham MJ, Culić O, Eraković V, et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol. 2005;517(1–2):132–143. doi:10.1016/j.ejphar.2005.05.023
   PubMed Web of Science ®Google Scholar
• ClinicalTrails.gov. Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early (ACHIEVE). ClinicalTrials.gov Identifier NCT04398004. US National Library of Medicine Available from: https://clinicaltrials.gov/ct2/show/NCT04398004. Accessed March 1, 2021.
   Google Scholar
• Krishnaveni M. A review on transfer factor an immune modulator. Drug Invent Today. 2013;5:153–156. doi:10.1016/j.dit.2013.04.002
   Google Scholar
• Castrejón Vázquez MI, Reséndiz-Albor AA, Ynga-Durand MA, et al. Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: experience from a Single Referral Pediatric Intensive Care Unit. Biomed Res Int. 2019;2019:8980506. doi:10.1155/2019/8980506
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al.; RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi:10.1056/NEJMoa2021436
   PubMed Web of Science ®Google Scholar
• Siemieniuk R, Rochwerg B, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. doi:10.1136/bmj.m3379
   PubMed Web of Science ®Google Scholar
• Meng WT, Qing L, Li CZ, et al. Ulinastatin: a Potential Alternative to Glucocorticoid in the Treatment of Severe Decompression Sickness. Front Physiol. 2020;11:273. doi:10.3389/fphys.2020.00273
   PubMed Web of Science ®Google Scholar
• Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME. Zinc and human health: an update. Arch Toxicol. 2012;86(4):521–534. doi:10.1007/s00204-011-0775-1
   PubMed Web of Science ®Google Scholar
• Samad N, Sodunke TE, Abubakar AR, et al. The Implications of Zinc Therapy in Combating the COVID-19 Global Pandemic. J Inflamm Res. 2021;14:527–550. doi:10.2147/JIR.S295377
   PubMed Web of Science ®Google Scholar
• Razzaque MS. COVID-19 Pandemic: can Maintaining Optimal Zinc Balance Enhance Host Resistance? Tohoku J Exp Med. 2020;251(3):175–181. doi:10.1620/tjem.251.175
   PubMed Web of Science ®Google Scholar
• Razzaque MS. COVID-19 pandemic: can boosting immune responses by maintaining adequate nutritional balance reduce viral insults? Adv Hum Biol. 2020;10(3):99–102. doi:10.4103/AIHB.AIHB_75_20
   Web of Science ®Google Scholar
• Razzaque MS. COVID-19 pandemic: can zinc supplementation provide an additional shield against the infection. Comput Struct Biotech J. 2021;19:1371–1378. doi:10.1016/j.csbj.2021.02.015
   PubMed Web of Science ®Google Scholar
• Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. Cell Death Discov. 2017;3(1):17071. doi:10.1038/cddiscovery.2017.71
   PubMedGoogle Scholar
• Haase H, Rink L. Functional significance of zinc-related signaling pathways in immune cells. Annu Rev Nutr. 2009;29(1):133–152. doi:10.1146/annurev-nutr-080508-141119
   PubMed Web of Science ®Google Scholar
• Wessels I, Rolles B, Rink L. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis. Front Immunol. 2020;11:1712. doi:10.3389/fimmu.2020.01712
   PubMed Web of Science ®Google Scholar
• Foster M, Samman S. Zinc and regulation of inflammatory cytokines: implications for cardiometabolic disease. Nutrients. 2012;4(7):676–694. doi:10.3390/nu4070676
   PubMed Web of Science ®Google Scholar
• Finzi E Treatment of SARS-CoV-2 with high dose oral zinc salts: a report on four patients. Int J Infect Dis. 2020; 99:307–309. doi: 10.1016/j.ijid.2020.06.006.
   Google Scholar
• Joachimiak MP. Zinc against COVID-19? Symptom surveillance and deficiency risk groups. PLoS Negl Trop Dis. 2021;15(1):e0008895. doi:10.1371/journal.pntd.0008895
   PubMed Web of Science ®Google Scholar
• Maggini S, Wintergerst ES, Beveridge S, Hornig DH. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br J Nutr. 2007;98(Suppl 1):S29–S35. doi:10.1017/S0007114507832971
   PubMed Web of Science ®Google Scholar
• Otieno CA. Coronavirus (COVID-19)-Kenyan case: a Review on prioritizing immunonutrition in Prevention and Management. World J Res Rev. 2020;11(2):1–13. doi:10.31871/WJRR.11.2.4
   Google Scholar
• Gasmi A, Tippairote T, Mujawdiya PK, et al. Micronutrients as immunomodulatory tools for COVID-19 management. Clin Immunol. 2020;220:108545. doi:10.1016/j.clim.2020.108545
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(5):349–361. doi:10.1038/nri2294
   PubMed Web of Science ®Google Scholar
• Weitzel LR, Mayles WJ, Sandoval PA, Wischmeyer PE. Effects of pharmaconutrients on cellular dysfunction and the microcirculation in critical illness. Curr Opin Anaesthesiol. 2009;22(2):177–183. doi:10.1097/ACO.0b013e328328d32f
   PubMed Web of Science ®Google Scholar
• Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6(12):1191–1197. doi:10.1038/ni1276
   PubMed Web of Science ®Google Scholar
• Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun. 2011;25(8):1725–1734. doi:10.1016/j.bbi.2011.07.229
   PubMed Web of Science ®Google Scholar
• ClinicalTrails.gov. The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm (NIH, 2020, Omega-3). ClinicalTrials.gov Identifier: NCT04483271. US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT04483271. Accessed February 27, 2021.
   Google Scholar
• Säemann MD, Böhmig GA, Osterreicher CH, et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J. 2000;14(15):2380–2382. doi:10.1096/fj.00-0359fje
   PubMed Web of Science ®Google Scholar
• Segain JP, Raingeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut. 2000;47(3):397–403. doi:10.1136/gut.47.3.397
   PubMed Web of Science ®Google Scholar
• Olaimat AN, Aolymat I, Al-Holy M, et al. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. NPJ Sci Food. 2020;4:17. doi:10.1038/s41538-020-00078-9
   PubMedGoogle Scholar
• Bowie AG, O’Neill LA. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol. 2000;165(12):7180–7188. doi:10.4049/jimmunol.165.12.7180
   PubMed Web of Science ®Google Scholar
• Jang IS, Ko YH, Moon YS, Sohn SH. Effects of Vitamin C or E on the Pro-Inflammatory Cytokines, Heat Shock Protein 70 and Antioxidant Status in Broiler Chicks under Summer Conditions. Asian Australas J Anim Sci. 2014;27(5):749–756. doi:10.5713/ajas.2013.13852
   PubMed Web of Science ®Google Scholar
• Stackaruk ML, Lee AJ, Ashkar AA. Type I interferon regulation of natural killer cell function in primary and secondary infections. Expert Rev Vaccines. 2013;12(8):875–884. doi:10.1586/14760584.2013.814871
   PubMed Web of Science ®Google Scholar
• Lee AJ, Mian F, Poznanski SM, et al. Type I Interferon Receptor on NK Cells Negatively Regulates Interferon-γ Production. Front Immunol. 2019;10:1261. doi:10.3389/fimmu.2019.01261
   PubMed Web of Science ®Google Scholar
• ClinicalTrails.gov. SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI). ClinicalTrials.gov Identifier: NCT04344184. US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT04344184. Accessed March 1, 2021.
   Google Scholar
• Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem. 2010;285(50):38751–38755. doi:10.1074/jbc.C110.185777
   PubMed Web of Science ®Google Scholar
• Diabetes TL. The Lancet Diabetes Endocrinology. Vitamin D and COVID-19: why the controversy? Lancet Diabetes Endocrinol. 2021;9(2):53. doi:10.1016/S2213-8587(21)00003-6
   PubMedGoogle Scholar
• Liuzzo G, Patrono C. COVID 19: in the eye of the cytokine storm. Eur Heart J. 2021;42(2):150–151. doi:10.1093/eurheartj/ehaa1005
   PubMed Web of Science ®Google Scholar
• Jesenak M, Brndiarova M, Urbancikova I, et al. Immune Parameters and COVID-19 Infection - Associations with Clinical Severity and Disease Prognosis. Front Cell Infect Microbiol. 2020;10:364. doi:10.3389/fcimb.2020.00364
   PubMed Web of Science ®Google Scholar
• McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am J Respir Crit Care Med. 2020;202(6):812–821. doi:10.1164/rccm.202005-1583OC
   PubMed Web of Science ®Google Scholar
• Aravindaram K, Yang NS. Anti-inflammatory plant natural products for cancer therapy. Planta Med. 2010;76(11):1103–1117. doi:10.1055/s-0030-1249859
   PubMed Web of Science ®Google Scholar
• Shapiro H, Lev S, Cohen J, Singer P. Polyphenols in the prevention and treatment of sepsis syndromes: rationale and pre-clinical evidence. Nutrition. 2009;25(10):981–997. doi:10.1016/j.nut.2009.02.010
   PubMed Web of Science ®Google Scholar
• Lewicka A, Szymański Ł, Rusiecka K, et al. Supplementation of Plants with Immunomodulatory Properties during Pregnancy and Lactation-Maternal and Offspring Health Effects. Nutrients. 2019;11(8):1958. doi:10.3390/nu11081958
   PubMed Web of Science ®Google Scholar
• Nugraha RV, Ridwansyah H, Ghozali M, Khairani AF, Atik N. Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: a Review of Their Mechanisms, Pros, and Cons. Evid Based Complement Alternat Med. 2020;2020:2560645. doi:10.1155/2020/2560645
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Durbin JE. Contribution of type III interferons to antiviral immunity: location, location, location. J Biol Chem. 2017;292(18):7295–7303. doi:10.1074/jbc.R117.777102
   PubMed Web of Science ®Google Scholar
• Lazear HM, Nice TJ, Diamond MS. Interferon-λ: immune Functions at Barrier Surfaces and Beyond. Immunity. 2015;43(1):15–28. doi:10.1016/j.immuni.2015.07.001
   PubMed Web of Science ®Google Scholar
• Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity. 2019;50(4):907–923. doi:10.1016/j.immuni.2019.03.025
   PubMed Web of Science ®Google Scholar
• Blazek K, Eames HL, Weiss M, et al. IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. J Exp Med. 2015;212(6):845–853. doi:10.1084/jem.20140995
   PubMed Web of Science ®Google Scholar
• Rivera A. Interferon Lambda’s New Role as Regulator of Neutrophil Function. J Interferon Cytokine Res. 2019;39(10):609–617. doi:10.1089/jir.2019.0036
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a Phase 2, placebo-controlled randomized trial. Lancet Respir Med. 2021. doi:10.1016/S2213-2600(20)30566-X
   PubMed Web of Science ®Google Scholar
• Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. Int Immunopharmacol. 2020;88:106903. doi:10.1016/j.intimp.2020.106903
   PubMed Web of Science ®Google Scholar
• Released by National Health Commission & National Administration of Traditional Chinese Medicine on March 3, 2020. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J. 2020;133(9):1087–1095. doi:10.1097/CM9.0000000000000819
   Google Scholar
• Veiga VC, Prats JAGG, Farias DLC, et al. Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomized controlled trial. BMJ. 2021;372:n84. doi:10.1136/bmj.n84
   PubMed Web of Science ®Google Scholar
• King A, Vail A, O’Leary C, et al. Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatol. 2020;2(7):e379–e381. doi:10.1016/S2665-9913(20)30160-0
   PubMedGoogle Scholar
• CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomized controlled trial. Lancet Respir Med. 2021. doi:10.1016/S2213-2600(20)30556-7
   Web of Science ®Google Scholar
• Robinson PC, Richards D, Tanner HL, Feldmann M. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol. 2020;2(11):E653–E655. doi:10.1016/S2665-9913(20)30309-X
   PubMedGoogle Scholar
• Starzonek J, Roscher K, Blüher M, et al. Effects of a blend of green tea and curcuma extract supplementation on lipopolysaccharide-induced inflammation in horses and ponies. Peer J. 2019;7:e8053. doi:10.7717/peerj.8053
   PubMed Web of Science ®Google Scholar
• Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. Int J Mol Sci. 2019;20(23):6008. doi:10.3390/ijms20236008
   PubMed Web of Science ®Google Scholar
• Robinson PC, Liew DFL, Liew JW, et al. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med. 2020;1(1):90–102. doi:10.1016/j.medj.2020.11.005
   PubMedGoogle Scholar
• Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018;24(Suppl 2):S10–S20. doi:10.1016/j.cmi.2017.12.025
   PubMed Web of Science ®Google Scholar
• McGowan EM, Haddadi N, Nassif NT, Lin Y. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19. Int J Mol Sci. 2020;21(19):7189. doi:10.3390/ijms21197189
   PubMed Web of Science ®Google Scholar
• Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem. 2004;279(15):15396–15401. doi:10.1074/jbc.M314291200
   PubMed Web of Science ®Google Scholar
• Du X, Zeng H, Liu S, et al. Mevalonate metabolism-dependent protein geranylgeranylation regulates thymocyte egress. J Exp Med. 2020;217(2):e20190969. doi:10.1084/jem.20190969
   PubMed Web of Science ®Google Scholar
• Lee MJ, Van Brocklyn JR, Thangada S, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science. 1998;279(5356):1552–1555. doi:10.1126/science.279.5356.1552
   PubMed Web of Science ®Google Scholar
• Liu CH, Thangada S, Lee MJ, Van Brocklyn JR, Spiegel S, Hla T. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell. 1999;10(4):1179–1190. doi:10.1091/mbc.10.4.1179
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. A new shield for a cytokine storm. Cell. 2011;146(6):861–862. doi:10.1016/j.cell.2011.08.027
   PubMed Web of Science ®Google Scholar
• Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs. 2015;29(7):565–575. doi:10.1007/s40263-015-0261-z
   PubMed Web of Science ®Google Scholar
• Foerch C, Friedauer L, Bauer B, Wolf T, Adam EH. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult Scler Relat Disord. 2020;42:102180. doi:10.1016/j.msard.2020.102180
   PubMedGoogle Scholar
• ClinicalTrails.gov. Fingolimod in COVID-19. ClinicalTrials.gov Identifier: NCT04280588. US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT04280588. Accessed February 27th, 2021.
   Google Scholar
• Zhao J, Zhu M, Jiang H, Shen S, Su X, Shi Y. Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus. Sci Rep. 2019;9(1):5272. doi:10.1038/s41598-019-41760-7
   PubMedGoogle Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402. doi:10.1016/S1473-3099(20)30132-8
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81(2):318–356. doi:10.1016/j.jinf.2020.04.017
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020. doi:10.1056/NEJMoa2031994
   Web of Science ®Google Scholar
• ClinicalTrails.gov. PRE-VENT Study in Hospitalized Patients with Severe COVID-19 With or Without Cancer. ClinicalTrials.gov Identifier: NCT04404361. US National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT04404361. Accessed March 1, 2021.
   Google Scholar
• Abubakar AR, Sani IH, Godman B, et al. Systematic Review on the Therapeutic Options for COVID-19: clinical Evidence of Drug Efficacy and Implications. Infect Drug Resist. 2020;13:4673–4695. doi:10.2147/IDR.S289037
   PubMed Web of Science ®Google Scholar
• Garcia P, Revet A, Yrondi A, Rousseau V, Degboe Y, Montastruc F. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): a VigiBase Study. Drug Saf. 2020;43(12):1315–1322. doi:10.1007/s40264-020-01013-3
   PubMed Web of Science ®Google Scholar
• Lane JCE, Weaver J, Kostka K, et al. Risk of depression, suicide, and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology. 2020. doi:10.1093/rheumatology/keaa771
   Google Scholar
• Bermejo-Martin JF, Kelvin DJ, Eiros JM, Castrodeza J, Ortiz de Lejarazu R. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J Infect Dev Ctries. 2009;3(3):159–161. doi:10.3855/jidc.18
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms. Front Immunol. 2018;9:302. doi:10.3389/fimmu.2018.00302
   PubMed Web of Science ®Google Scholar
• He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80(6):445–452. doi:10.1159/000321374
   PubMed Web of Science ®Google Scholar
• Clinical Trial Arena. Study finds azithromycin and doxycycline ineffective for Covid-19; 2021. Available from: https://www.clinicaltrialsarena.com/news/uk-study-azithromycin-doxycycline/#:~:text=The%20University%20of%20Oxford%20ineffective%20treatments%20for%20Covid%2D19. Accessed March 2, 2021.
   Google Scholar
• Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomized clinical trial. Lancet. 2020;396(10256):959–967. doi:10.1016/S0140-6736(20)31862-6
   PubMed Web of Science ®Google Scholar
• Viza D, Pizza G, De Vinci C, Brandi G, Ablashi D. Transfer Factor as an Option for Managing the COVID-19 Pandemic. Folia Biol. 2020;66(3):86–90.
   PubMed Web of Science ®Google Scholar
• ClinicalTrails.gov. Efficacy of Transfer Factor to Prevent Upper Respiratory Tract Infections in Healthy Adults. ClinicalTrials.gov Identifier: NCT01106183. US National Library of Medicine. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01106183. Accessed March 1, 2021.
   Google Scholar
• Mahase E. Covid-19: low dose steroid cuts death in ventilated patients by one-third, trial finds. BMJ. 2020;369:m2422. doi:10.1136/bmj.m2422
   PubMedGoogle Scholar
• Liu J, Zheng X, Huang Y, Shan H, Huang J. Successful use of methylprednisolone for treating severe COVID-19. J Allergy Clin Immunol. 2020;146(2):325–327. doi:10.1016/j.jaci.2020.05.021
   PubMed Web of Science ®Google Scholar
• Kapugi M, Cunningham K. Corticosteroids. Orthop Nurs. 2019;38(5):336–339. doi:10.1097/NOR.0000000000000595
   PubMed Web of Science ®Google Scholar
• Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39(7):2085–2094. doi:10.1007/s10067-020-05190-5
   PubMed Web of Science ®Google Scholar
• Pau AK, Aberg J, Baker J, et al. Convalescent Plasma for the Treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med. 2021;174(1):93–95. doi:10.7326/M20-6448
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235–249. doi:10.1016/j.cell.2008.02.043
   PubMed Web of Science ®Google Scholar